Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Ogawa, E. n., Toyoda, H. n., Iio, E. n., Jun, D. W., Huang, C. F., Enomoto, M. n., Hsu, Y. C., Haga, H. n., Iwane, S. n., Wong, G. n., Lee, D. H., Tada, T. n., Liu, C. H., Chuang, W. L., Hayashi, J. n., Cheung, R. n., Yasuda, S. n., Tseng, C. H., Takahashi, H. n., Tran, S. n., Yeo, Y. H., Henry, L. n., Barnett, S. D., Nomura, H. n., Nakamuta, M. n., Dai, C. Y., Huang, J. F., Yang, H. I., Lee, M. H., Jung Jun, M. n., Kao, J. H., Eguchi, Y. n., Ueno, Y. n., Tamori, A. n., Furusyo, N. n., Yu, M. L., Tanaka, Y. n., Nguyen, M. H., Ahn, S. B., Azuma, K. n., Dohmen, K. n., Yoon Jeong, J. n., Jung, J. H., Kajiwara, E. n., Kato, M. n., Kawano, A. n., Koyanagi, T. n., Ooho, A. n., Park, S. H., Satoh, T. n., Shimoda, S. n., Song, D. S., Takahashi, K. n., Yeh, M. L., Yoon, E. L. 2019

Abstract

The cure rate of hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) for patients with active and inactive hepatocellular carcinoma (HCC) may differ, but well-controlled studies are limited. We aimed to evaluate DAA outcomes in a large East Asian HCV/HCC population compared to HCV/non-HCC patients.Using data from the REAL-C registry (Hong Kong, Japan, South Korea, and Taiwan), we used propensity score matching (PSM) to match HCC and non-HCC (1:1) groups for age, sex, cirrhosis, prior treatment, HCV genotype, treatment regimen, baseline platelet count, HCV RNA, total bilirubin, alanine aminotransferase, and albumin level to evaluate DAA treatment outcomes in a large population of HCV/HCC compared to HCV/non-HCC patients.We included 6,081 patients (HCC, n=465; non-HCC, n=5,616) treated with interferon-free DAAs. PSM of the entire study population yielded 436 matched pairs with similar baseline characteristics. There was no statistically significant difference in the overall SVR rate of the HCC (92.7%) and non-HCC (95.0%) groups. Rates of treatment discontinuation, adverse effects, and death were also similar between the HCC and non-HCC groups. Among patients with HCC, those with active HCC had a lower SVR than inactive HCC cases (85.5% vs. 93.7%, P=0.03). On multivariable analysis, active HCC, but not inactive HCC, was significantly associated with lower SVR (OR 0.28, P=0.01) when compared to non-HCC.Active HCC but not inactive HCC was independently associated with lower SVR compared to non-HCC patients undergoing DAA therapy, though cure rate was still relatively high (85%) in active HCC patients.

View details for DOI 10.1093/cid/ciz1160

View details for PubMedID 31777940